Neither thiocolchicoside nor tolperisone should be used as intramuscular therapy for acute low back pain
The evidence-based approach for acute low back pain that has not responded to oral analgesics is to optimize oral therapy with NSAIDs and/or skeletal muscle relaxants, not to escalate to intramuscular injections of these specific agents.
Why This Recommendation
Guideline-Based Treatment Algorithm
The American College of Physicians/American Pain Society guidelines 1 provide clear direction:
First-line therapy: Acetaminophen or NSAIDs (oral)
- NSAIDs are more effective than acetaminophen by approximately 10 points on a 100-point VAS scale
- Assess cardiovascular and gastrointestinal risk factors before prescribing
Second-line therapy: Add oral skeletal muscle relaxants for short-term relief
- Good evidence supports skeletal muscle relaxants for acute low back pain 2
- All are associated with CNS adverse effects (primarily sedation)
- No compelling evidence that different skeletal muscle relaxants differ in efficacy or safety 1
Third-line therapy: Consider opioids or tramadol judiciously for severe, disabling pain not controlled by the above 1
The Specific Problem with Your Question
Neither thiocolchicoside nor tolperisone are FDA-approved or guideline-recommended for low back pain treatment 1. The "drug" evidence provided 3 is actually for tolterodine (DETROL LA), an anticholinergic medication for overactive bladder—completely unrelated to musculoskeletal pain management.
Evidence on Thiocolchicoside
While some studies show thiocolchicoside reduces pain compared to placebo 4, 5, 6, 7, the clinical significance is questionable:
- A 2024 meta-analysis 8 found thiocolchicoside significantly reduced VAS scores by only -0.49 points at 2-3 days and -0.82 points at 5-7 days
- These reductions are below the minimally important difference (MID) of 1 point on a 0-10 scale
- All included studies were at high risk of bias
- Overall certainty of evidence was very low 8
- The European Medicines Agency has raised safety concerns about thiocolchicoside 8
Evidence on Tolperisone
The evidence for tolperisone in acute low back pain is even weaker:
- A 2018 systematic review 9 suggests tolperisone may be effective but provides no specific efficacy data
- One observational study 10 showed benefit when combined with nimesulide, but this was non-controlled
- No high-quality RCTs specifically evaluate tolperisone for acute low back pain
Critical Pitfalls to Avoid
Route of administration misconception: Intramuscular administration does not provide superior efficacy for these medications—it simply changes pharmacokinetics without improving outcomes
Polypharmacy without evidence: The combination studies 4, 5, 11 show thiocolchicoside + diclofenac is marginally better than diclofenac alone, but the incremental benefit is clinically insignificant and doesn't justify IM administration
Ignoring established guidelines: The ACP/APS guidelines 1 explicitly recommend oral skeletal muscle relaxants (like cyclobenzaprine, methocarbamol, or tizanidine) with proven efficacy, not these agents
What You Should Actually Do
For acute low back pain not responding to oral analgesics:
Optimize oral NSAID therapy (if not contraindicated)
- Ensure adequate dosing and duration
- Consider GI protection if needed
Add an oral skeletal muscle relaxant 2
- Options: cyclobenzaprine, methocarbamol, tizanidine
- Short-term use (days to 1-2 weeks maximum)
- Warn about sedation
If still inadequate: Consider tramadol or short-term opioid therapy 1
- Assess risk for abuse/addiction
- Time-limited course
- Reassess if no response
Consider non-pharmacologic therapy: Spinal manipulation has small to moderate short-term benefits for acute low back pain 1
The intramuscular route should be reserved for patients who cannot take oral medications, and even then, standard NSAIDs (like ketorolac) would be more appropriate than thiocolchicoside or tolperisone, neither of which have robust evidence supporting their use in this context.